Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Pan, Szu Yu ^a,b,c   Chiang, Wen Chih ^a   Chen, Ping Min ^a   Liu, Heng Hsiu ^d   Chou, Yu Hsiang ^a   Lai, Tai Shuan ^a   Lai, Chun Fu ^a   Chiu, Yen Ling ^b   Lin, Wan Yu ^d   Chen, Yung Ming ^a   Chu, Tzong Shinn ^a   Lin, Shuei Liong ^a,c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT;

AGED; CHRONIC KIDNEY FAILURE; DIALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTILIZATION;

AGED; DIALYSIS; FEMALE; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85014830547     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44013     Document Type: Article

References (64)

1. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, hospitalization. N Engl J Med 351, 1296-1305 (2004).
2. Wen, C. P., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371, 2173-2182 (2008).
3. Jha, V., et al. Chronic kidney disease: global dimension and perspectives. The Lancet 382, 260-272 (2013).
4. Hung, S. C., Lin, Y. P., Tarng, D. C. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years. J Formos Med Assoc 113, 3-10 (2014).
5. Chang, Y. T., et al. DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys. J Clin Invest 126, 721-731 (2016).
6. Yeh, P. Y., Liao, F. L., Lin, S. L. Is the renoprotective effect of erythropoietin in chronic kidney disease a myth. J Formos Med Assoc 112, 655-656 (2013).
7. Bahlmann, F. H., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110, 1006-1012 (2004).
8. Menne, J., et al. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 18, 2046-2053 (2007).
9. Chen, X., et al. The administration of erythropoietin attenuates kidney injury induced by ischemia/reperfusion with increased activation of Wnt/beta-catenin signaling. J Formos Med Assoc 114, 430-437 (2015).
10. Cassis, P., et al. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int 81, 903-918 (2012).
11. Coldewey, S. M., et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the betacommon receptor. Kidney Int 84, 482-490 (2013).
12. Bahlmann, F. H., Fliser, D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 18, 15-20 (2009).
13. Robb, L., et al. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci USA 92, 9565-9569 (1995).
14. Gouva, C., Nikolopoulos, P., Ioannidis, J. P., Siamopoulos, K. C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66, 753-760 (2004).
15. Choukroun, G., et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 23, 360-368 (2012).
16. Singh, A. K., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355, 2085-2098 (2006).
17. Pfeffer, M. A., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361, 2019-2032 (2009).
18. Szczech, L. A., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74, 791-798 (2008).
19. Solomon, S. D., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363, 1146-1155 (2010).
20. Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M., Jaber, B. L. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61, 44-56 (2013).
21. US Food and Drug Administration. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. 2011. http://www. fda. gov/drugs/drugsafety/ucm259639. htm. Accessed Febuary 7, 2016.
22. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis, Suppl 3, May 2006 47, S1-S146.
23. National Institute for Health and Care Excellence: Anaemia management in chronic kidney disease: update 2015. (Clinical guideline ng8. ) http://www. nice. org. uk/guidance/ng8 Accessed Apr 18, 2015.
24. Regidor, D., McClellan, W. M., Kewalramani, R., Sharma, A., Bradbury, B. D. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant 26, 1583-1591 (2011).
25. Winkelmayer, W. C., Mitani, A. A., Goldstein, B. A., Brookhart, M. A., Chertow, G. M. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med 174, 699-707 (2014).
26. United States Renal Data System. 2014 USRDS annual data report: An overview of the epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2014).
27. Chiu, Y. L., et al. Outcomes of Stage 3-5 Chronic Kidney Disease before End-Stage Renal Disease at a Single Center in Taiwan. Nephron Clin Pract 109, c109-c118 (2008).
28. Chen, P. M., et al. Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs. Am J Med 128, 68-76 (2015).
29. Chen, P. M., et al. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J Formos Med Assoc 113, 219-226 (2014).
30. Cox, D. R. Regression Models and Life-Tables. J R Stat Soc Series B Stat Methodol 34, 187-220 (1972).
31. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. http://www. whocc. no/Accessed Apr 18, 2015.
32. Levey, A. S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145, 247-254 (2006).
33. Levey, A. S., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150, 604-612 (2009).
34. WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157-163 (2004).
35. Sharples, E. J., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15, 2115-2124 (2004).
36. Eto, N., et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72, 455-463 (2007).
37. Garcia, D. L., Anderson, S., Rennke, H. G., Brenner, B. M. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85, 6142-6146 (1988).
38. Brochu, E., et al. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10, 1440-1446 (1999).
39. Lebel, M., Rodrigue, M. E., Agharazii, M., Lariviere, R. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 19, 1286-1292 (2006).
40. Hu, M. C., et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int 84, 468-481 (2013).
41. Leist, M., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242 (2004).
42. McCullough, P. A., et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 37, 549-558 (2013).
43. Tapolyai, M., Kadomatsu, S., Perera-Chong, M. r. hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 4, 3 (2003).
44. Mercadal, L., et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 7, 35-42 (2012).
45. Fehr, T., et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66, 1206-1211 (2004).
46. Eschbach, J. W., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111, 992-1000 (1989).
47. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300, 573-578 (1990).
48. Cody, J. D., Hodson, E. M. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev 1, CD003266 (2016).
49. Nishikawa, K., et al. Influence of chronic kidney disease on hospitalization, chronic dialysis, mortality in Japanese men: a longitudinal analysis. Clin Exp Nephrol, doi: 10. 1007/s10157-016-1293-5 (2016).
50. Tsubakihara, Y., et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14, 240-275 (2010).
51. Goodkin, D. A., et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14, 3270-3277 (2003).
52. The National Health Research Institutes and the Taiwan Society of Nephrology. 2014 Annual Report on Kidney Disease in Taiwan. 36-41 (Taiwan Ministry of Health and Welfare, 2015).
53. Masakane, I., et al. An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013). Ther Apher Dial 19, 540-574 (2015).
54. Yang, W. C., Hwang, S. J. Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 23, 3977-3982 (2008).
55. Hwang, S. J., et al. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant 25, 2616-2624 (2010).
56. Cooper, B. A., et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363, 609-619 (2010).
57. Rosansky, S. J., Eggers, P., Jackson, K., Glassock, R., Clark, W. F. Early start of hemodialysis may be harmful. Arch Intern Med 171, 396-403 (2011).
58. Susantitaphong, P., et al. GFR at initiation of dialysis and mortality in CKD: a meta-analysis. Am J Kidney Dis 59, 829-840 (2012).
59. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3, 1-150 (2013).
60. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, stratification. Am J Kidney Dis 39, S1-266 (2002).
61. Regidor, D. L., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17, 1181-1191 (2006).
62. Forsblom, C., et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22, 537-544 (2011).
63. Li, L., et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 59, 504-512 (2012).
64. Chen, X. Score Test of Proportionality Assumption for Cox Models. Proceedings of Western Users of SAS Software 2008.